Earnings Insights · Stryker (SYK) · Q3 FY2026

Stryker (SYK) Q3 FY2026: Stryker Q3 2026 Earnings: Orthopaedics Slowdown Overshadows Strong MedSurg Growth

By AlgovestIQ ResearchPublished

Share

Read Stryker’s results announcement (Form 8-K, filed Oct 29, 2026)

Key earnings findings

Stryker (SYK) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Stryker reported Q3 FY2026 revenue of $6.52B against the $6.62B analyst estimate, 1.5% below it, and EPS of $3.52 against the $3.55 analyst estimate, 0.8% below it.
  2. Management expects fourth-quarter organic growth to be similar to the 7.7% achieved in the third quarter.
  3. SYK closed at $291.86 on Oct 30, 2026, down 6.4% from $311.75 on Oct 29, 2026, the last close before the results were released.

Sources: Stryker results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Stryker beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$6.52B
$6.62B
-1.5%
EPS
$3.52
$3.55
-0.8%
  • Revenue surprise across the last 8 reported quarters has ranged from -5.0% to 3.1%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Stryker reported third-quarter revenue of $6.5B, up 7.7% year over year, while adjusted EPS rose 10.3% to $3.52. The quarter was operationally solid in MedSurg, Neurotechnology and capital equipment, but management said results fell short of its expectations as hip and knee procedure growth slowed and execution issues limited Orthopaedics’ share gains.

The central change in the investment story is that Stryker’s broad portfolio continues to grow at a high-single-digit rate, but its largest joint-reconstruction categories face a softer market and a slower commercial response than management anticipated. Margin expansion and expense discipline protected adjusted earnings, though GAAP profits were reduced by a $293M goodwill impairment and other special items.

Earnings Snapshot

MetricReportedChange
Net sales$6.5B+7.7%
Organic sales growth7.7%—
MedSurg and Neurotechnology sales$3.7B+9.2%
Orthopaedics sales$2.9B+5.7%
Reported operating income margin15.9%Down 280 bps
Adjusted operating income margin26.2%Up 60 bps
Reported diluted EPS$1.96-11.7%
Adjusted diluted EPS$3.52+10.3%
Operating cash flow, nine months$3.3B+13.9%
Share repurchases in Q3$1.0B—
Cash and cash equivalents$3.3BDown from $4.0B at year-end 2025

The Bigger Story

Stryker’s 7.7% organic growth remained healthy, but the company’s growth profile became less uniform during the quarter. MedSurg and Neurotechnology grew 9.1% organically, supported by capital equipment demand, Endoscopy, Medical and Vascular. Orthopaedics grew 5.9%, with strong Ortho Tech growth offset by weak hips and knees.

Management estimates the hip and knee market has grown roughly 2.5% this year, a meaningful slowdown from recent years. It cited higher insurance premiums and deductibles, increased pre-authorization denials, regional disruption in Europe and the Middle East, and government funding decisions as factors delaying procedures.

Stryker also acknowledged that it has not been gaining share in hips and knees at its historical rate. The first-quarter cybersecurity incident and a July SAP implementation in Orthopaedics distracted commercial teams and delayed visibility into underlying order trends. Management does not believe it lost major blocks of business to competitors, but it said its teams were less effective in driving new-product adoption and competitive conversions.

The distinction matters. A market slowdown could reverse with improved patient affordability or procedure volumes, while a sustained decline in Stryker’s relative execution would represent a more company-specific risk. Management views the current weakness as a combination of both factors.

Revenue and Operating Performance

Consolidated sales rose 7.7% on a reported, constant-currency and organic basis. Foreign exchange had no effect on quarterly sales, while pricing contributed just 0.1 percentage point of growth. Increased unit volume drove nearly all organic growth.

MedSurg and Neurotechnology remained the growth engine

MedSurg and Neurotechnology revenue increased 9.2% to $3.7B, including 9.1% organic growth. U.S. sales increased 9.6%, while international sales rose 7.8% as reported and 7.7% in constant currency.

Endoscopy was the strongest major business line, with sales up 13.9% to $1.0B. U.S. Endoscopy growth reached 13%, aided by demand for operating-room infrastructure and renovations, as well as continued double-digit Sports Medicine growth. The shoulder implant portfolio was a contributor, with management pointing to continued adoption of its expanded product range.

Medical sales rose 9.7% to $1.1B. U.S. growth was 10%, with Sage and Smart Care delivering double-digit gains. Management said Smart Care had its best quarter to date, reflecting improved integration of the Vocera and care.ai businesses and rising customer interest in virtual nursing tools.

Vascular sales increased 8.0% to $566M, including 7.4% growth in constant currency. U.S. sales grew 13%, but the reported result included a one-time regulatory approval milestone payment from Stryker’s Peripheral Vascular joint venture in China. That benefit partly offset revenue lost from a continuing supply disruption. Management said product availability and inventory levels should continue normalizing through year-end.

Instruments grew 5.1% to $996M. U.S. growth of 4.8% was moderated by deferred neurosurgical capital purchases ahead of the Sonopet 3 ultrasonic aspiration platform launch. Sonopet 3 received FDA 510(k) clearance in October.

Orthopaedics was held back by hips and knees

Orthopaedics revenue rose 5.7% to $2.9B, or 5.9% organically. U.S. sales increased 6.5%, while international sales rose 4.5% in constant currency.

The key weakness was in large-joint reconstruction. Knee sales increased only 1.1% to $635M, including 1.3% growth in the U.S. Hip sales fell 1.0% to $453M, with U.S. hips down 0.6%. Management attributed the result to slower procedure demand and less effective execution behind newer products, including Mako RPS and Triathlon Gold.

By contrast, Ortho Tech revenue increased 15.8% to $754M, including 16.0% growth in constant currency. The result reflected strong Mako sales, a balance of new installations and upgrades to the Mako 4 platform, and robust demand for orthopedic power tools.

Trauma and Extremities grew 5.3% to $1.0B, despite a difficult prior-year comparison. U.S. growth was 4.5%, and management expects a stronger fourth quarter. Upper-extremity products continued to perform well, helped by the Mako Shoulder application and Stryker’s differentiated shoulder portfolio.

Management said extremities have not experienced the same demand slowdown affecting hips and knees. It views shoulder replacement as a newer and faster-growing market, supported by improving clinical outcomes and product innovation.

Profitability and Margins

Adjusted EPS increased 10.3% to $3.52, outpacing revenue growth. Adjusted net earnings rose 10.1% to $1.4B, while adjusted operating income margin expanded 60 basis points to 26.2%.

Adjusted gross margin increased 40 basis points to 65.4%, helped by operational efficiencies and a net tariff benefit. Selling, general and administrative expenses were flat as a percentage of sales on an adjusted basis at 32.8%, supporting operating leverage despite the slower-than-expected sales performance.

Reported earnings told a different story. GAAP operating income declined 8.9% to $1.0B, and reported operating margin fell to 15.9% from 18.7%. Reported EPS declined 11.7% to $1.96.

The primary difference was a $293M goodwill impairment recorded during the quarter. Reported results also included $153M of structural optimization and other special charges, including $77M related to the sale of the Spinal Implants business, as well as $175M of purchased-intangible amortization. These items materially reduced GAAP profitability but were excluded from adjusted earnings.

Management expects full-year adjusted other income and expense of approximately $400M and an adjusted effective tax rate of 15.5% to 16%.

Demand, Customers and Pricing

Capital demand remained a major source of support. Management said the company’s order book remains elevated across the portfolio, particularly in Medical and other capital-oriented businesses. However, it also cited the need to manage production and delivery execution carefully to meet that demand, which contributed to a more cautious year-end outlook.

The company said pricing should make a modest positive contribution to full-year sales growth. Management expects positive pricing in much of MedSurg, while Orthopaedics pricing is expected to remain slightly negative as the company seeks to preserve share and navigate normal contracting dynamics. Stryker said it does not conduct bulk sales in hips and knees, which it believes makes its revenue trends more reflective of underlying procedure activity.

Peripheral Vascular remains a near-term execution issue. Supply disruption reduced revenue, although management said manufacturing progress should allow availability to normalize through the end of 2026. The expected launch of AVS’ IVL platform in 2027 could provide a new growth driver if regulatory approval is received.

What Is Stryker’s Guidance for Full-Year 2026?

Stryker now expects:

  • Organic net sales growth of 6.5% to 7.0%
  • Adjusted EPS of $14.80 to $14.90

Management expects fourth-quarter organic growth to be similar to the 7.7% achieved in the third quarter. That outlook assumes the hip and knee procedure environment remains at current levels, Peripheral Vascular supply constraints continue to ease, and capital demand stays strong.

The company said its revised outlook reflects softer hip and knee procedure trends, lingering Peripheral Vascular supply constraints and a more conservative view of operational execution risk in capital equipment sales. Management expects gross-margin gains and expense discipline to limit the impact of the sales shortfall on adjusted EPS.

For 2027, Stryker did not provide formal guidance. Management said it expects to grow at the high end of its underlying markets, while acknowledging that its weighted-average market growth rate is likely lower than the roughly 6% estimate discussed a year ago because of slower joint-replacement demand.

Balance Sheet, Cash Flow and Capital

Stryker ended the quarter with $3.3B in cash and cash equivalents, down from $4.0B at year-end 2025. Long-term debt declined to $14.2B from $14.9B at year-end.

Nine-month operating cash flow increased 13.9% to $3.3B. Capital expenditures were $605M, compared with $493M a year earlier, while acquisitions totaled $481M, far below the $5.0B deployed in the prior-year period.

The company repurchased $1.0B of stock in the third quarter and received an additional $3.0B authorization from its board in October. Management characterized buybacks as opportunistic rather than a change in its capital-allocation priorities, with acquisitions remaining the first priority.

Stryker also completed the acquisition of ZuriMED, adding FiberLocker technology for orthopedic soft-tissue augmentation and rotator cuff repair. Separately, it announced an investment in CMR Surgical and an agreement to serve as exclusive U.S. sales agent for the Versius soft-tissue robotic platform. Management views the arrangement as a lower-risk way to establish a U.S. commercialization presence before potentially pursuing an acquisition of CMR in the future.

What Investors Should Watch

1. Hip and knee procedure trends

The largest near-term issue is whether joint-replacement demand remains near management’s estimated 2.5% market growth rate or begins to recover. Procedure growth, patient affordability and payer authorization trends will determine whether current softness is temporary or more persistent.

2. Orthopaedics execution and share gains

Stryker needs to restore adoption of Mako RPS and Triathlon Gold, while using its planned power hip impaction solution to close a portfolio gap in 2027. Improvement would be visible in hip and knee growth moving ahead of the market rather than merely matching it.

3. Peripheral Vascular supply recovery

The business benefited from one-time China joint-venture revenue in the third quarter, masking some continuing supply-related pressure. Investors should watch whether inventory normalization translates into a cleaner underlying revenue recovery before the anticipated AVS IVL launch.

4. Capital equipment conversion

Demand and the order book remain elevated, but management has become more cautious about its ability to convert orders into revenue on schedule. Production capacity, delivery execution and continued hospital capital spending will be important to fourth-quarter performance.

5. Margin durability

Adjusted operating margin expanded 60 basis points despite slower Orthopaedics growth. Sustained gross-margin improvement and cost discipline would support earnings even if joint-replacement volumes remain subdued, while margin pressure would suggest the sales mix is becoming more consequential.

AlgovestIQ Takeaway

Stryker’s third quarter demonstrated the value of its diversified medical technology portfolio. MedSurg and Neurotechnology delivered 9.1% organic growth, capital demand remained strong, and adjusted margins improved enough for adjusted EPS growth to exceed revenue growth. Ortho Tech, Endoscopy, Medical and Smart Care all provided evidence that the company retains multiple growth drivers beyond joint reconstruction.

The concern is not that Stryker’s business has broadly weakened. Rather, its historically important hips and knees businesses are facing both a less favorable procedure environment and an execution gap. Higher patient out-of-pocket costs and authorization friction may be outside the company’s control, but commercial distraction following the cybersecurity incident and SAP implementation is not.

Management’s full-year outlook still implies a solid finish, with fourth-quarter growth expected to remain around the third-quarter rate. Yet the company is no longer relying on an acceleration in joint reconstruction to support that result. The near-term growth burden has shifted toward MedSurg, Trauma and Extremities, Ortho Tech and capital equipment.

The central investment question is whether Stryker can return Orthopaedics to market-leading growth once its execution issues clear and new products gain traction. Evidence of renewed hip and knee share gains, normalized Peripheral Vascular supply and continued margin expansion would strengthen that case. Continued softness in joint procedures or further delays in capital-equipment conversion would keep the focus on whether the company’s organic growth rate can remain near its historical range.

How did SYK stock react?

SYK closed at $291.86 on Oct 30, 2026, down 6.4% from $311.75 on Oct 29, 2026, the last close before the results were released.

SessionCloseChange
Oct 29, 2026 (before release)$311.75—
Oct 30, 2026$291.86-6.4%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Stryker Q3 FY2026 earnings call transcript, as of Oct 29, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Stryker Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 29, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 29, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Every reported figure is checked against Stryker's earnings release and call transcript before publication. Not investment advice.